Connor Clark & Lunn Investment Management Ltd. Has $1.02 Million Stake in Horizon Pharma PLC (HZNP)  Caroline Horne | Aug 17th, 2018
Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 40.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 61,775 shares of the biopharmaceutical company's stock after purchasing an additional 17,850 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Horizon Pharma were worth $1,023,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. venBio Select Advisor LLC boosted its holdings in shares of Horizon Pharma by 16.3% during the first quarter. venBio Select Advisor LLC now owns 5,158,683 shares of the biopharmaceutical company's stock valued at $73,253,000 after acquiring an additional 722,500 shares during the period. Northern Trust Corp boosted its holdings in shares of Horizon Pharma by 0.5% during the first quarter. Northern Trust Corp now owns 1,967,642 shares of the biopharmaceutical company's stock valued at $27,940,000 after acquiring an additional 9,366 shares during the period. Redwood Investments LLC boosted its holdings in shares of Horizon Pharma by 43.9% during the first quarter. Redwood Investments LLC now owns 1,320,081 shares of the biopharmaceutical company's stock valued at $18,745,000 after acquiring an additional 402,610 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Horizon Pharma by 252.2% during the first quarter. Point72 Asset Management L.P. now owns 1,312,900 shares of the biopharmaceutical company's stock valued at $18,643,000 after acquiring an additional 940,100 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Horizon Pharma by 299.2% during the first quarter. Millennium Management LLC now owns 1,124,465 shares of the biopharmaceutical company's stock valued at $15,967,000 after acquiring an additional 842,814 shares during the period. 84.62% of the stock is owned by institutional investors. Get Horizon Pharma alerts:
HZNP stock opened at $20.60 on Friday. The stock has a market capitalization of $3.49 billion, a P/E ratio of 17.42, a P/E/G ratio of 1.26 and a beta of 1.43. Horizon Pharma PLC has a fifty-two week low of $11.17 and a fifty-two week high of $21.25. The company has a debt-to-equity ratio of 2.19, a current ratio of 1.70 and a quick ratio of 1.63.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.17. The business had revenue of $302.84 million during the quarter, compared to the consensus estimate of $275.51 million. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. The company's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.41 earnings per share. analysts anticipate that Horizon Pharma PLC will post 1.41 EPS for the current fiscal year.
In other Horizon Pharma news, Chairman Timothy P. Walbert sold 83,353 shares of the business's stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $16.17, for a total value of $1,347,818.01. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website . Also, EVP Brian K. Beeler sold 15,433 shares of the business's stock in a transaction dated Friday, June 8th. The stock was sold at an average price of $17.58, for a total transaction of $271,312.14. The disclosure for this sale can be found here . Insiders sold 116,717 shares of company stock valued at $1,907,999 in the last ninety days. Corporate insiders own 3.90% of the company's stock.
Several equities research analysts recently weighed in on HZNP shares. Mizuho reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Horizon Pharma in a report on Wednesday, August 8th. Jefferies Financial Group upped their price objective on shares of Horizon Pharma from $21.00 to $23.00 and gave the stock a "buy" rating in a report on Thursday, August 9th. Stifel Nicolaus upped their price objective on shares of Horizon Pharma from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, June 18th. ValuEngine downgraded shares of Horizon Pharma from a "buy" rating to a "hold" rating in a report on Thursday, July 5th. Finally, Piper Jaffray Companies reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Horizon Pharma in a report on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. Horizon Pharma presently has an average rating of "Buy" and a consensus price target of $20.27.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
See Also: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP). Horizon Pharma Horizon Pharm